ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Novartis Will Not Support Further Development of Fevipiprant for Asthma
December 18, 2019Novartis announced topline results from its pivotal global Phase III LUSTER-11 and LUSTER-22 studies exploring the efficacy and safety of the investigational oral, once-daily ... -
Novartis’ fevipiprant fails to meet clinically relevant threshold in phase III asthma studies
December 17, 2019Novartis announced that its asthma treatment fevipiprant has failed to meet the clinically relevant threshold in Luster phase III studies. -
World Asthma Day: can fevipiprant revolutionise asthma treatment?
May 07, 2019World Asthma Day aims to raise awareness of the burden of asthma. Increasingly, the standard of care for asthma, reliever and preventer inhalers, are being discovered to be insufficient in a number of ways.
Pharma Sources Insight January 2025
